Staff editor
Microbiomepost discussed with Herbert Tilg, Medizinische Universitat Innsbruck, Austria, about the importance of gut microbiome for intestinal and not intestinal health.
Osnat Tirosh, Head of Microbiome Research & Innovation at Biomica, talks about the validation of the mechanism of action of BMC333 consortia through pre-clinical studies in IBD models.
Christophe Roca, Head of Pilot Department at Sacco System, talks about development and GMP production of Live Biotherapeutics for all applications.
Juan Basterra, CEO at Mikrobiomik, talks about the interim results on MBK-01, the first intestinal microbiota-based biological drug in phase 3 for both primary episode and recurrence of Clostridioides dificile.
With all aspects of LBPs covered in the summit, the 8th Microbiome Movement Summit in Boston became the hub for sharing the latest insights in LBP research and development.
Ongoing Phase 3 trial built on positive data from Phase 2 HERACLES study and ongoing early access program (EAP) in France: both datasets showed that MaaT013 was well-tolerated in immunocompromised…
Video
Sponsored by
Nina Vinot (TargEDys International Sales Director) talks about a new promising way to isolate, study and bring to the market innovative probiotics.
Karl Alex Hedin (Technical University of Denmark) talks about the potential role of genetically engineering Saccharomyces boulardii to produce an anti-obesity peptide.
Industry
Sponsored by
The microbiological laboratory applying AI to specific analysis activities.
Gwenael Jan (STLO - INRAE, France) talks about the growing interest and knowledge of Propionibacteria, a peculiar actinobacteria that has the potential to become a next generation probiotic.
